Comparative Pharmacology
Head-to-head clinical analysis: AMELUZ versus VISUDYNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMELUZ versus VISUDYNE.
AMELUZ vs VISUDYNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMELUZ (aminolevulinic acid hydrochloride) is a photosensitizer that is converted to protoporphyrin IX (PpIX) in rapidly proliferating cells. Upon exposure to light of appropriate wavelength and intensity, PpIX generates reactive oxygen species, leading to phototoxicity and cell death in abnormal tissues.
Verteporfin, a benzoporphyrin derivative, is a photosensitizer activated by nonthermal red light (689 nm). Upon activation, in the presence of oxygen, it generates reactive oxygen species (e.g., singlet oxygen) causing local damage to endothelial cells, leading to occlusion of abnormal choroidal neovasculature.
Apply one 30 g tube of AMELUZ (aminolevulinic acid hydrochloride) topical solution 10% to the lesion and surrounding 0.5 cm of normal skin once, followed by photodynamic therapy using red light (630 nm, 37 J/cm²) 14-18 hours later.
6 mg/m2 body surface area administered as a 10-minute intravenous infusion, followed by laser light activation at 689 nm 15 minutes after start of infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours after topical application. Systemic exposure is minimal due to limited percutaneous absorption.
5-6 hours (verteporfin); clinical context: supports once-daily dosing for photodynamic therapy
Primarily hepatic metabolism; <2% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Biliary/fecal: >90% unchanged; renal: <1%
Category C
Category C
Photosensitizing Agent
Photosensitizing Agent